SLG
ABMD

Stanley-Laman Group’s Abiomed Inc ABMD Stock Holding History

Stanley-Laman Group’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11,072
Closed -$1.89M – 336
2019
Q4 		$1.89M Sell
11,072
-2,111
-16% -$391K 0.45% 59
2019
Q3 		$2.35M Sell
13,183
-27
-0.2% -$5.84K 0.58% 49
2019
Q2 		$3.44M Buy
13,210
+259
+2% +$68.7K 0.83% 37
2019
Q1 		$3.7M Sell
12,951
-671
-5% -$223K 0.9% 35
2018
Q4 		$4.43M Buy
+13,622
New +$4.73M 1.23% 12
2014
Q1 		– Sell
-55,104
Closed -$1.47M – 350
2013
Q4 		$1.47M Buy
+55,104
New +$1.36M 0.32% 97

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Stanley-Laman Group's ABMD Position: Q1 2020 in Review

Stanley-Laman Group sold out of Abiomed Inc (ABMD) in Q1 2020, closing a stake of 11,072 shares — an estimated $1.89M sold.

Stanley-Laman Group first reported a position in ABMD in Q4 2013 and held it in 6 quarters. The position peaked at $4.43M in Q4 2018. 412 funds tracked by Wall St. Rank hold ABMD as of Q1 2020.

  • Stanley-Laman Group reported no remaining Abiomed Inc position as of Q1 2020 after selling out during the quarter.
  • Stanley-Laman Group sold 11,072 Abiomed Inc shares in Q1 2020, an estimated $1.89M.
  • Stanley-Laman Group first reported a position in Abiomed Inc in Q4 2013 and held it in 6 quarters.
  • Stanley-Laman Group's Abiomed Inc position peaked at $4.43M in Q4 2018.
  • 412 funds tracked by Wall St. Rank held Abiomed Inc as of Q1 2020.

Based on Stanley-Laman Group's 13F filing for Q1 2020, filed 12 May 2020.